Management in Intensive Care Unit of Life-threatening Keto-Acidosis (MILKA)

Patients hospitalized in intensive care between January 2014 and December 2023 for ketoacidosis complicated by organ failure in participating departments.

Study Overview

Status

Completed

Conditions

Detailed Description

Analysis of patients with International Statistical Classification of Diseases and Related Health Problems coding compatible with inclusion

  • Selection of patients eligible for inclusion based on review of medical records (verification of inclusion and non-inclusion criteria)
  • Telephone contact and sending of the information letter on participation in the study and research of the patient's non-opposition to his participation and the processing of his data.
  • Collection of retrospective data
  • Phone call to collect prospective data

Study Type

Observational

Enrollment (Actual)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Bobigny, France, 93000
        • Avicenne
      • Colombes, France, 92700
        • Louis Mourier
      • Le Kremlin-Bicêtre, France, 94270
        • BICETRE
      • Paris, France, 75012
        • Saint-Louis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized in intensive care between January 2014 and December 2023 for ketoacidosis complicated by organ failure in participating departments.

Description

Inclusion Criteria:

  • Major (age ≥ 18 years old)
  • Hospitalized in intensive care between January 2014 and December 2023 for ketoacidosis complicated by organ failure in the participating departments.
  • Diagnosis of ketoacidosis judged to be the main cause of the severity of the clinical condition.
  • Blood potential hydrogen < 7.15 and bicarbonates < 10mmol/L in the first 12 hours of treatment.
  • Presenting at least one of the 3 organ failures during hospitalization among:
  • Use of extra-renal purification for acute renal failure
  • Administration of pressor amines
  • Use of mechanical ventilation

Exclusion Criteria:

  • Metabolic acidosis primarily of an origin other than ketonic
  • Refusal to participate or opposition to the processing of their data
  • Patient under guardianship or curators

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
evaluate the incidence of mortality in intensive care units of patients hospitalized for severe diabetic ketoacidosis.
Time Frame: up to 6 months
Percentage of mortality in intensive care units in patients admitted for ketoacidosis complicated by organ failure.
up to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 2, 2024

Primary Completion (Actual)

February 2, 2024

Study Completion (Actual)

June 14, 2024

Study Registration Dates

First Submitted

July 25, 2022

First Submitted That Met QC Criteria

August 2, 2022

First Posted (Actual)

August 4, 2022

Study Record Updates

Last Update Posted (Actual)

June 20, 2024

Last Update Submitted That Met QC Criteria

June 18, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-A00455-38

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ketoacidosis

Search Similar Trials